狄诺塞麦用量是多少？

(denosumab, also known as AMG-162, trade name Prolia) is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures.

What is the dosage of denosumab?

Denosumab is a prescription drug. It must be prescribed by a doctor according to the condition of the disease, and must be taken according to the doctor's instructions, including usage, dosage, medication time, etc. Do not use medication by yourself according to the instructions on the medication.

Recommended usage and dosage of denosumab: (1) Denosumab can only be injected subcutaneously, not intravenously, intramuscularly or intradermally. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Malignant hypercalcemia: 20 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

There are currently no studies on the effectiveness and safety of this product in children, so denosumab is not recommended for children.

There is no need to adjust the dosage for the elderly and patients with renal insufficiency. For patients with severe renal insufficiency and those undergoing dialysis treatment, blood calcium monitoring should be carried out, and calcium and vitamin D supplementation should be paid attention to.

It is not clear whether (denosumab) can be excreted in breast milk. Breast-feeding women should weigh the importance of this product to them and choose to discontinue the drug or stop breastfeeding.